Jo Bednarik

Company: Eli Lilly & Company

Job title: Executive Director, Medical Development, Diabetes, & Obesity

Seminars:

Can GLP-1 Agonists Represent a Meaningful Therapeutic Option for People with Obstructive Sleep Apnea (OSA)? 9:30 am

Discussing the clinical and economic burden of OSA Understanding the basic pathophysiology of the disease and why GLP-1 RAs may be a valid treatment option Evaluating the current treatment options for OSA and exploring the benefits GLP-1 RAs may bring Reflecting on challenges and future plans to expand GLP-1 therapies into this areaRead more

day: Conference Day One